Impax Laboratories, Inc. IPXL
Set alert
18.30 0.00 0.00%
At close · Jun 28
17.40 Day range 18.95
52-week range unavailable
- Open
- 18.20
- Prev close
- 18.30
- Mkt cap
- 0
- Vol
- 3.01M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.40
- High
- 18.95
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 9, 2018
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 22.33
Analyst view
Consensus: hold
Hold
Price target (mean) 22.33 +22.0% upside
Now 18.30
- Target (low)
- 16.00
- Target (mean)
- 22.33
- Target (high)
- 35.00
Ratings (0m) 13 3 buy · 9 hold · 1 sell
- Strong buy1
- Buy2
- Hold9
- Sell1
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 13
- 2 months ago 13
- 3 months ago 13
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.16 | 0.02 – 0.30 | 0.11 | +45.5% | 182.15M | -1.2% | 13 |
| Next quarter | 0.24 | 0.14 – 0.38 | 0.18 | +33.3% | 194.28M | -3.9% | 8 |
| Current year | 1.08 | 0.91 – 1.42 | 0.63 | +71.4% | 788.70M | +1.7% | 8 |
| Next year | 1.36 | 0.99 – 1.73 | 1.08 | +25.9% | 834.12M | +5.8% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 30, 2018 | Barclays | Initiated | — | Overweight |
| Mar 6, 2018 | SunTrust Robinson Humphrey | Initiated | — | Buy |
| Sep 27, 2017 | Goldman Sachs | Initiated | — | Neutral |
| Jul 30, 2017 | Canaccord Genuity | Initiated | — | Hold |
| Jul 17, 2017 | PiperJaffray | Upgrade | — | Neutral |
| Jun 15, 2017 | Cantor Fitzgerald | Initiated | — | Overweight |
| Mar 7, 2017 | Susquehanna | Downgrade | — | Neutral |
| Mar 7, 2017 | Deutsche Bank | Upgrade | — | Buy |
| Dec 27, 2016 | Janney Capital | Initiated | — | Neutral |
| Nov 13, 2016 | Wallachbeth | Downgrade | — | Hold |
| Nov 6, 2016 | Bank of America | Downgrade | — | Underperform |
| Sep 26, 2016 | Goldman Sachs | Upgrade | — | Neutral |
| Aug 14, 2016 | Northland Securities | Upgrade | — | Outperform |
| Jun 28, 2016 | BMO Capital | Initiated | — | Market Perform |
| Jun 20, 2016 | Bank of America | Upgrade | — | Neutral |
| Jun 5, 2016 | Goldman Sachs | Initiated | — | Sell |
| Apr 18, 2016 | Northland Securities | Initiated | — | Market Perform |
| Feb 16, 2016 | Raymond James | Upgrade | — | Market Perform |
| Jan 5, 2016 | JP Morgan | Initiated | — | Neutral |
| Oct 5, 2015 | BTIG Research | Initiated | — | Buy |
| Sep 28, 2015 | Nomura | Initiated | — | Neutral |
| Jul 20, 2015 | Susquehanna | Initiated | — | Positive |
| Jul 19, 2015 | Susquehanna | Initiated | — | Positive |
| Jun 2, 2015 | Raymond James | Initiated | — | Underperform |
| Apr 16, 2015 | UBS | Downgrade | — | Sell |
| Apr 7, 2015 | Deutsche Bank | Initiated | — | Hold |
| Mar 10, 2015 | PiperJaffray | Upgrade | — | Overweight |
| Feb 10, 2015 | Goldman Sachs | Downgrade | — | Neutral |
| Nov 4, 2014 | PiperJaffray | Downgrade | — | Neutral |
| Oct 21, 2014 | JMP Securities | Initiated | — | Outperform |